Skip to main content

Research Repository

Advanced Search

A multi-centre, randomized, double-blind, placebo-controlled phase II study to assess the effect of Serelaxin versus placebo on high-sensitivity cardia troponin I (hs-cTnl) release in patients with chronic heart failure after exercise when used in additio

People Involved

Professor Andrew Clark A.L.Clark@hull.ac.uk

Dr Parin Shah P.Shah@hull.ac.uk

Type of Project Project
Status Project Complete
Funder(s) Novartis UK
Value £40,924.00
Project Dates Feb 18, 2016 - Feb 17, 2017

You might also like

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Dec 31, 2019
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study dru... Read More